pruritus

Skincare Mondays | Oat for Oncology Patients
Dermatologic side effects are among the most frequent unexpected side effects of cancer treatments.1,2 Targeted therapies are associated with a lower incidence of systemic adverse events, but a higher incidence of dermatological AEs - including acneiform rash and pruritus.3 Skin toxicities can have a dramatic negative impact on QOL and overall success of treatment therapies.3 Skin toxicities oft …
Doxepin Therapeutic Cheat Sheet
DoxepinAs dermatologists, pruritus (or itch) is one of the most frequent symptoms that we encounter. The broad spectrum of itch severity in patients with various dermatologic conditions suggests a need for a host of “tools” or medications that dermatologists should have in their toolbox. In this publication, we continue our Therapeutic Cheat Sheet series by highlighting the uses of Doxepin in dermato …
Doxepin
Atopic Dermatitis (AD) Treatment Initiation and Monitoring
atopic dermatitis (AD)During the recent DERM2O22 NP/PA CME conference held July 28-31, 2022, Drs. David Cohen, Brad Glick, and Adam Friedman led a case-based panel discussion on atopic dermatitis (AD) treatment initiation and monitoring. This article provides a summary of their discussion and recommendations.  CASE 1 51-year-old male with a 20-year history of AD. The patient was first seen in September 2015 with BSA …
atopic dermatitis (AD)
Skincare Mondays | Colloidal Oatmeal: Composition, Benefits & Mechanism of Action
Colloidal OatmealColloidal oatmeal has a long history of use in the treatment of dermatologic disease. Oat is composed of various phytochemicals which contribute to its wide-ranging function and clinical use in atopic dermatitis and other skin conditions resulting from an impaired skin barrier and inflammation. OAT COMPOSITION & BENEFITS The main components of colloidal oatmeal are polysaccharides (including …
Colloidal Oatmeal
Tralokinumab-ldrm Therapeutic Cheat Sheet
tralokinumabAtopic dermatitis is a common, chronic, life-altering disease. With its visibility and debilitating pruritus, atopic dermatitis significantly impacts our patients’ quality of life. For those with resistant and extensive disease, we are happy to have numerous new systemic agents at our disposal, one being tralokinumab, an IL-13 antagonist. We continue our series, Therapeutic Cheat Sheet, with a c …
tralokinumab